Pfizer to build R&D facility in
Wuhan, China


25th November 2009



Pfizer is expanding its R&D efforts in China and announced
plans to build a new facility.

An agreement has been signed to establish a new Pfizer R&D
centre in Wuhan, which the firm says represents an expansion
of its existing facility in Shanghai. Once the new plant is built,
the company expects the number of employees to grow to 200
within three years but gave no details about the financial investment
involved.

Pfizer noted that its Wuhan operation will liaise with local research
institutes and universities “utilising the rich resources of local talent
and existing industry capabilities to develop research collaborations”.
It stressed that Shanghai will remain “the operations hub of
Pfizer's R&D effort in China”.

Allan Gabor, the company’s North Asia president, noted that it is the
first to establish a significant R&D presence in China’s Central/Western
region. He added that the Wuhan centre will be an integral part of
Pfizer's global R&D operations “while being closely aligned with the
Chinese government’s strategy on biopharmaceutical industry
development in the region."

The site will be based at the Wuhan National Bioindustry Base, or
Biolake, the construction for which started in November last year.


SOURCE : PHARMATIMES

Also from 2009

Pfizer is now placing its trust in biotechnology
for future growth